Story perspectives

Revolutionary Drug Cuts Heart Disease Risk by 95%

4/14/2025

49 4

Summary

Story summary

Lepodisiran, an innovative experimental drug, has shown remarkable potential by slashing lipoprotein(a) levels—an elusive genetic risk factor for heart disease—by up to 95% in trials. Unlike traditional cholesterol, Lp(a) remains stubbornly unchanged by diet or exercise. Though not yet on the market, lepodisiran could revolutionize the fight against this hidden cardiovascular threat, making testing Lp(a) levels crucial for proactive health management.

1 of 1

Story summary

Lepodisiran, an innovative experimental drug, has shown remarkable potential by slashing lipoprotein(a) levels—an elusive genetic risk factor for heart disease—by up to 95% in trials. Unlike traditional cholesterol, Lp(a) remains stubbornly unchanged by diet or exercise. Though not yet on the market, lepodisiran could revolutionize the fight against this hidden cardiovascular threat, making testing Lp(a) levels crucial for proactive health management.